BUSINESS

• Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
  August 30, 2016

• Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
  August 30, 2016

• Mylan, Pfizer Recalling 2 Generic Products in Japan
  August 29, 2016

• Vimpat Filed for Monotherapy Approval in Japan: Daiichi Sankyo, UCB
  August 29, 2016

• Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
  August 29, 2016

• CSL Behring Seeks Approval of Human Prothrombin Complex
  August 26, 2016

• Actemra Filed for Weekly Dosage for Inadequately Controlled RA
  August 26, 2016

• Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
  August 26, 2016

• Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
  August 26, 2016

• Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
  August 25, 2016

• Announcement: Real World Data Japan 2016 to Be Held at Westin Tokyo Hotel on October 18-19
  August 25, 2016

• Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
  August 24, 2016

• Canaglu-Tenelia Combo Filed in Japan: Mitsubishi Tanabe
  August 23, 2016

• GSK Paid 6.2 Billion Yen to Doctors, Medical Institutions in 2015
  August 23, 2016

• New Treatment Options Arriving in Multiple Myeloma Arena
  August 23, 2016

• Sales per Drug Rep Check in at 168 Million Yen in FY2015: Survey
  August 22, 2016

• Oncolys to Set Up US Subsidiary to Ratchet Up Licensing Activities
  August 22, 2016

• Evidence for Actair Sublingual Tablets “Sets It Apart from Other Therapies”: Shionogi
  August 22, 2016

• Oncolys, Kyoto Pref. University of Medicine to Study OBP-801 for Glaucoma
  August 19, 2016

• Amgen Confident of Getting Handsome Slice of Japan Biosimilar Market: Exec
  August 19, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 480
• 481
• 482
• 483
• 484
• 485
• 486
• 487
• 488
• …
• Next ›
• 最終 »